Aspen Neuroscience files for IPO

By Elias Schisgall Aspen Neuroscience filed for an initial public offering. The company did not say how many shares it would list or at what price, according to a Friday filing with the Securities and Exchange Commission. The clinical-stage biotechnology company said it plans to use proceeds from the IPO in part to fund the development of its lead product candidate, a potential cell therapy treatment for Parkinson's disease called sasineprocel. The company applied to list shares on the Nasdaq Global Select Market under the symbol ASPE. Write to Elias Schisgall at elias.schisgall@wsj.com (END) Dow Jones Newswires October 09, 2026 16:21 ET (20:21 GMT) Copyright (c) 2026 Dow Jones & Company, Inc. The statements in this document shall not be considered as an objective or independent explanation of the matters. Please note that this document (a) has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and (b) is not subject to any prohibition on dealing ahead of the dissemination or publication of investment research.